HDL-C in post-menopausal women: An important therapeutic target

International Journal of Cardiology

Volumn 124, Issue 3, 2008, Pages 275-282

  Collins, Peter ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Coronary heart disease; High density lipoprotein cholesterol; Menopause; Women

Indexed keywords

EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; TRIACYLGLYCEROL;

ANGIOCARDIOGRAPHY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIETARY INTAKE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MENOPAUSE; METABOLIC SYNDROME X; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CLOFIBRIC ACID; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; NIACIN; POSTMENOPAUSE; RISK FACTORS; SURVIVAL RATE;

EID: 40049085158     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.06.009     Document Type: Review

References (88)

1. Yusuf S., Reddy S., Ounpuu S., and Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104 (2001) 2746-2753
2. Petersen S., Peto V., Rayner M., Leal J., Luengo-Fernandez R., and Gray A. European cardiovascular disease statistics (2005), British Heart Foundation, London
3. Schaefer E.J., Lamon-Fava S., Cohn S.D., et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 35 (1994) 779-792
4. Stevenson J.C., Crook D., and Godsland I.F. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98 (1993) 83-90
5. Matthews K.A., Meilahn E., Kuller L.H., Kelsey S.F., Caggiula A.W., and Wing R.R. Menopause and risk factors for coronary heart disease. N Engl J Med 321 (1989) 641-646
6. Kannel W.B., and Wilson P.W. Risk factors that attenuate the female coronary disease disadvantage. Arch Intern Med 155 (1995) 57-61
7. Hall G., Collins A., Csemiczky G., and Landgren B.M. Lipoproteins and BMI: a comparison between women during transition to menopause and regularly menstruating healthy women. Maturitas 41 (2002) 177-185
8. Matthews K.A., Kuller L.H., Sutton-Tyrrell K., and Chang Y.-F. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke 32 (2001) 1104-1111
9. Jenner J.L., Ordovas J.M., Lamon-Fava S., et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 87 (1993) 1135-1141
10. Luc G., et al., on behalf of the PRIME Study Group. Lipoprotein(a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 163 (2002) 377-384
11. Nerbrand C., Lidfeldt J., Nyberg P., Schersten B., and Samsioe G. Serum lipids and lipoproteins in relation to endogenous and exogenous female sex hormones. The Women's Health in the Lund Area (WHILA) Study. Maturitas 48 (2004) 161-169
12. Li Z., McNamara J.R., Fruchart J.C., et al. Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. J Lipid Res 37 (1996) 1886-1896
13. Carr M.C. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88 (2003) 2404-2411
14. Zago V., Sanguinetti S., Brites F., et al. Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis 177 (2004) 203-210
15. The IDF consensus worldwide definition of the metabolic syndrome. Available from www.idf.org/home/index.cfm?unode=32EF2063-B966-468F-928C-A5682A4E3910 (9 May 2006).
16. Toth M.J., Tchernof A., Sites C.K., and Poehlman E.T. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 24 (2000) 226-231
17. Stampfer M.J., and Colditz G.A. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 20 (1991) 47-63
18. Belalcazar L.M., and Ballantyne C.M. Defining specific goals of therapy in treating dyslipidaemia in the patient with low high-density lipoprotein cholesterol. Prog Cardiovasc Dis 41 (1998) 151-174
19. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
20. Grady D., Herrington D., Bittner V., et al., on behalf of the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002) 49-57 [erratum, JAMA 2002;288:1064]
21. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
22. Herrington D.M., Rebouissin D.M., Brosnihan K.B., et al. Effect of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 343 (2000) 522-529
23. Anderson G.L., Limacher M., Assaf A.R., et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
24. Hsia J., Langer R.D., Manson J.E., et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 166 (2006) 357-365
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
26. Van Gaal L.F., Wauters M.A., and De Leeuw I.H. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 21 suppl 1 (1997) S5-S9
27. International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease [online]. Available from http://www.athero.org [9 May 2006].
28. Mosca L., Appel L.J., Benjamin E.J., et al. American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109 (2004) 672-693
29. Mosca L., Banka C.L., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
30. Chapman M.J., et al., European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20 (2004) 1253-1268
31. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1999) 1383-1389
32. Sacks F.M., Pfeffer M.A., Moyle L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
33. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
34. Hague W., Forder P., Simes J., Hunt D., Tonkin A., and LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: Results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Am Heart J 145 (2003) 643-651
35. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomised placebo-controlled trial. Lancet 360 (2002) 7-22
36. La Rosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
37. Moghadasian M.H. Statins and menopause. Drugs 62 (2002) 2421-2431
38. Clearfield M., Downs J.R., Weis S., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med 10 (2001) 971-981
39. Herrington D.M., et al., on behalf of the HERS Study Group. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 105 (2002) 2962-2967
40. Sever P.S.S., Dahlöf B., Poulter N., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
41. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
42. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
43. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease PROSPER: a randomised controlled trial. Lancet 360 (2002) 1623-1630
44. Vittinghoff E., et al., on behalf of the Estrogen/progestin Replacement Study Research Group. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 138 (2003) 81-89
45. Mosca L., Merz N.B., Blumenthal R.S., et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 111 (2005) 488-493
46. Sacks F.M., Tonkin A.M., Shepherd J., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 102 (2000) 1893-1900
47. Baigent C., et al., on behalf of the Cholesterol Treatment Trialists' (CTC) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
48. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., and Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-94. Arch Intern Med 163 (2003) 427-436
49. Bass K.M., Newschaffer C.J., Klag M.J., and Bush T.L. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 153 (1993) 2209-2216
50. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
51. Kannel W.B. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 114 (1987) 413-419
52. Shai I., Rimm E.B., Hankinson S.E., et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women. Potential implications for clinical guidelines. Circulation 110 (2004) 2824-2830
53. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62 (1977) 707-714
54. Assmann G., Schulte H., von Eckardstein A., and Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 suppl (1996) S11-S20
55. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
56. Manninen V., Elo M.O., Frick M.H., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260 (1988) 641-651
57. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
58. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
59. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171 (2003) 1-13
60. Birjmohun R.S., Hutten B.A., Kastelein J.J.P., and Stroes E.S.G. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 (2005) 185-197
61. The UK HDL-C Consensus Group. Role of fibrates in reducing coronary risk: a UK Consensus. Curr Med Res Opin 20 (2004) 241-247
62. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
63. Keech A., Simes R.J., Barter P., et al., on behalf of the FIELD Study Investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
64. Ericsson C.G., Hamsten A., Nilsson J., Grip L., and de Faire U. Angiographic assessment of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996) 849-853
65. Frick M.H., Syvanne M., Nieminen M.S., et al. Prevention of angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96 (1997) 2137-2143
66. Wierzbicki A.S., Mikhailidis D.P., Wray R., et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 19 (2003) 155-168
67. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 16 (1995) 5-13
68. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120-122
69. Prueksaritanont T., Subramanian R., Fang X., et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30 (2002) 505-512
70. Davidson M.H., Armani A., McKenney J.M., and Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 99 suppl (2007) 3C-18C
71. Grundy S.M., Vega G.L., Yuan Z., et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 95 (2005) 462-468
72. Pasternak R.C., Smith S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins. J Am Coll Cardiol 40 (2002) 568-573
73. Farnier M., Freeman M.W., Macdonell G., et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 26 (2005) 897-905
74. McKenney J.M., Farnier M., Lo K.W., et al. Safety and efficacy of long-term administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 47 (2006) 1584-1587
75. McCormack P.L., and Keating G.M. Prolonged-release nicotinic acid. A review of its use in the treatment of dyslipidaemia. Drugs 65 (2005) 2719-2740
76. Morgan J.M., Capuzzi D.M., Guyton J.R., et al. Treatment effect of NIASPAN, a controlled-release nicotinic acid, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1 (1996) 195-202
77. Goldberg A., Alagona Jr. P., Capuzzi D.M., et al. Multiple-dose efficacy and safety of an extended-release form of nicotinic acid in the management of hyperlipidemia. Am J Cardiol 85 (2000) 1100-1105
78. Morgan J.M., Capuzzi D.M., Baksh R.I., et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 91 (2003) 1432-1436
79. Canner P.L., Furberg C.D., Terrin M.L., and McGovern M.E. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 95 (2005) 254-257
80. McKenney J.M., Jones P.H., Bays H.E., et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 192 (2007) 432-437
81. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
82. Zhao X.-Q., Morse J., Chait A., et al. Simvastatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome. J Am Coll Cardiol 39 suppl A (2002) 242A [abstract 1130-73]
83. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
84. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 22 (2006) 2243-2250
85. Knopp R.H., Alagona P., Davidson M., et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47 (1998) 1097-1104
86. Capuzzi D.M., Guyton J.R., Morgan J.M., et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 82 suppl 12A (1998) 74U-81U
87. Grundy S.M., et al., on behalf of the Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 162 (2002) 1568-1576
88. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 suppl 1 (2006) S4-S42